Medicines on the FDA drug shortage list, with which forms and strengths are affected, who makes them and when supply is expected back.
5 medicines
-
Bumetanide Resolved 12 products · updated September 30, 2026
Cardiovascular
Product Availability Expected supply / notes Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-102-07)
MSN Laboratories Private Limited—
Resolved · September 30, 2026Bumetanide, Injection, .25 mg/1 mL (NDC 65219-570-04)
Fresenius Kabi USA, LLC—
Resolved · September 30, 2026Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6007-10)
Hikma Pharmaceuticals USA, Inc.—
Resolved · September 30, 2026Bumetanide, Injection, 0.25 mg/mL, 10 mL (NDC 72205-102-01)
MSN Laboratories Private Limited—
Resolved · September 30, 2026Bumetanide, Injection, 1 mg/4 mL (0.25 mg/mL) (NDC 83301-0080-2)
Mullan Pharmaceutical Inc.—
Resolved · September 30, 2026Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6008-10)
Hikma Pharmaceuticals USA, Inc.—
Resolved · September 30, 2026Bumetanide, Injection, 0.25 mg/mL, 4mL (NDC 72205-101-01)
MSN Laboratories Private Limited—
Resolved · September 30, 2026Bumetanide, Injection, .25 mg/1 mL (NDC 65219-572-10)
Fresenius Kabi USA, LLC—
Resolved · September 30, 2026Bumetanide, Injection, 2.5 mg/10 mL (0.25 mg/mL) (NDC 83301-0081-2)
Mullan Pharmaceutical Inc.—
Resolved · September 30, 2026Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-101-07)
MSN Laboratories Private Limited—
Resolved · September 30, 2026Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-04)
Sagent Pharmaceuticals—
Resolved · September 30, 2026Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-10)
Sagent Pharmaceuticals—
Resolved · September 30, 2026 -
Albuterol Sulfate Resolved 3 products · updated August 27, 2026
Pediatric, Pulmonary/Allergy
Product Availability Expected supply / notes Albuterol Sulfate, Solution, 2.5 mg/.5 mL (NDC 64980-642-03)
Rising Pharma Holdings, Inc.—
Resolved · August 27, 2026Albuterol Sulfate, Solution, 2.5 mg/.5 mL (NDC 0487-9901-30)
Nephron Pharmaceuticals Corporation—
Resolved · August 27, 2026Albuterol Sulfate, Solution, 2.5 mg/.5 mL (NDC 76204-027-01)
Ritedose Pharmaceuticals, LLC—
Resolved · August 27, 2026 -
Peginterferon Alfa-2a Resolved 2 products · updated August 27, 2026
Antiviral
Product Availability Expected supply / notes Pegasys, Injection, 180 ug/.5 mL (NDC 82154-0451-4)
pharmaand GmbH (pharma&)—
Resolved · August 27, 2026Pegasys, Injection, 180 ug/1 mL (NDC 82154-0449-1)
pharmaand GmbH (pharma&)—
Resolved · August 27, 2026 -
Rifapentine Resolved 1 product · updated August 6, 2026
Anti-Infective
Product Availability Expected supply / notes Priftin, Tablet, Film Coated, 150 mg (NDC 0088-2102-24)
Sanofi-Aventis U.S. LLC—
Resolved · August 6, 2026 -
Triamcinolone Acetonide Resolved 1 product · updated July 31, 2026
Ophthalmology
Product Availability Expected supply / notes Triesence, Injection, 40 mg/1 mL (NDC 82667-800-01)
Harrow Eye, LLC—
Resolved · July 31, 2026
Reading the list: a medicine stays on the FDA list while any of its products is short. "Available" next to a product means that particular strength or pack can currently be ordered. If your pharmacy cannot fill a prescription, ask the pharmacist or prescriber about another strength, form or an alternative — do not ration or stop a medicine on your own.
Source: FDA Drug Shortages Database, via openFDA. Updated here twice a day; last update October 31, 2026 14:40. openFDA data are not validated for clinical use — confirm with the FDA source or your pharmacist.